BRASILIA – Brazilian fitness regulator Anvisa announced Tuesday that it approved Level 3 clinical trials for a COVID-19 vaccine developed through Johnson and Johnson’s pharmaceutical subsidiary, Janssen.
Brazil is the country at the time most affected by coronavirus cases and deaths after the United States, which has led many corporations to seek clinical trials here. The Johnson-Johnson candidate vaccine is the fourth to be approved for human trials in Brazil, Anvisa said in his statement. (Reporting through Ricardo Brito; written through Jake Spring; edited through Alex Richardson)
Sign up for news from the National Post, a department of Postmedia Network Inc.
An error has occurred, provide a valid email address.
A welcome email is on the way. If you don’t see it, check your unwanted folder.
The next factor in the newsletter will soon be in your inbox.
We found a challenge when you signed up. Check it again
Postmedia is committed to remaining a civilized forum for discussion and encouraging all readers to express their views on our articles. Comments can take up to an hour to moderate before appearing on the site. We ask that you keep your comments applicable and respectful. We’ve enabled email notifications. You will now receive an email if you get a reaction to your comment, an update to a comment thread that follows, or if a user follows it. Check out our network regulations for more data and main points on how to adjust your email settings.
365 Bloor Street East, Toronto, Ontario, M4W 3L4
© 2020 National Post, a department of Postmedia Network Inc. All rights reserved. Unauthorized dissemination, transmission or dissemination is strictly prohibited.
This uses cookies to personalize your content (including ads) and allows us to analyze our traffic. Learn more about cookies here. By using our site, you agree to our terms of use and our privacy policy.